Breakthrough T1D

Between 80–100 words — The foundation operates a hybrid funding model. A traditional grant-making arm supports academic research and early-stage science, while the in-house T1D Fund makes direct equity investments in private biotech and medical-device companies targeting commercial therapies, devices, and diagnostics for type 1 diabetes. By co-investing alongside firms like Sanofi Ventures, the fund applies venture-capital discipline to mission-driven science. Returns from successful exits can be recycled into new research grants, creating a self-replenishing funding cycle that amplifies philanthropic dollars.

The foundation's overall strategy is overseen by CEO Aaron Kowalski. The T1D Fund — the venture-philanthropy vehicle within Breakthrough T1D — is managed by a separate investment team that evaluates and executes equity deals in biotech companies. Because the fund co-invests with commercial VCs and holds membership in the New England Venture Capital Association, its investment committee operates with a professional investor mandate, evaluating opportunities for both scientific merit and potential financial return to the foundation.

The T1D Fund is a venture philanthropy vehicle housed within Breakthrough T1D, not an independent firm. It deploys equity capital into for-profit startups advancing T1D therapies, with the foundation acting as the limited partner. This structure allows Breakthrough T1D to hold board seats, negotiate milestone-based terms, and syndicate with traditional biotech VCs — a degree of market engagement that a pure grant-making charity cannot easily achieve.

The fund targets private life-science companies developing drugs, devices, diagnostics, and digital health tools specifically for type 1 diabetes. Investments span clinical-stage therapeutics, glucose-sensing hardware, insulin-delivery systems, and software platforms that improve disease management. The fund's mandate covers both disease-modifying treatments and curative approaches, including cell therapy and immune-modulation assets.

Yes. The foundation maintains active strategic partnerships with the Helmsley Charitable Trust and the Steve Morgan Foundation, syndicating capital for large-scale research initiatives like the Type 1 Diabetes Grand Challenge. On the venture side, Sanofi Ventures appears as a frequent co-investor across the T1D Fund's portfolio. These collaborations pool patient-capital and domain expertise that individual philanthropies rarely achieve alone.

Funding comes from individual donations, corporate sponsorships, planned giving, and investment returns. The foundation also operates a cryptocurrency donation portfolio, accepting digital-asset contributions. Unlike a single-family office or an endowment with a monolithic capital base, Breakthrough T1D aggregates philanthropic support from a broad constituency of T1D-affected families, volunteers, and aligned institutions.

The name change to Breakthrough T1D signals an evolution from being a disease-specific funding intermediary to a brand that reflects its expanded role in directly catalyzing commercial therapies. Operationally, the shift consolidates the grant-making and venture arms under one narrative — a research engine that not only funds breakthroughs but actively steers them toward regulatory approval and patient access through market mechanisms.